Cambridge UK, 9th August 2017 – Bactevo’s Totally Integrated Medicines Engine (TIME) technology has been featured in the latest issue of Genetic Engineering & Biotechnology News (GEN). Click here to read the article.
Bactevo has built a unique and game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Utilising its paradigm shift in the speed, efficiency and quality of drug discovery, as well as massively enhancing safety profiling to improve clinical success, Bactevo is developing breakthrough medicines for the treatment of diseases that involve defects in mitochondrial function, such as MELAS and LHON, as well as diseases of the central nervous system, such as Parkinson’s, Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS). Further information can be found at www.bactevo.com.
For further information, contact:
|Bactevo Ltd||Halsin Partners (media)|
|David Williams, PhD||Mike Sinclair|
|Chief Executive Officer||Partner|
|Tel: +44(0)1223 423506||Tel: +44 (0) 20 7318 2955|
|Email: email@example.com||Email: firstname.lastname@example.org|